Misplaced Pages

Talaporfin

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is the current revision of this page, as edited by Maxim Masiutin (talk | contribs) at 01:18, 11 February 2024 (Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. Added s2cid. | Use this bot. | #UCB_Other). The present address (URL) is a permanent link to this version.

Revision as of 01:18, 11 February 2024 by Maxim Masiutin (talk | contribs) (Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. Added s2cid. | Use this bot. | #UCB_Other)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Chemical compound

Pharmaceutical compound
Talaporfin
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		IV
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • N-{acetyl}-L-aspartic acid
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC38H41N5O9
Molar mass711.772 g·mol
3D model (JSmol)
SMILES
  • CCC1=C2C=C3C(=C(C(=N3)C(=C4((C(=N4)C=C5C(=C(C(=CC(=C1C)N2)N5)C=C)C)C)CCC(=O)O)CC(=O)N(CC(=O)O)C(=O)O)C(=O)O)C
InChI
  • InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-/t18-,22-,30-/m0/s1
  • Key:VSEIDZLLWQQJGK-WSUYNKMOSA-N
  (what is this?)  (verify)

Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a chlorin based photosensitizer used in photodynamic therapy (PDT).

It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength.

It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.

References

  1. Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, Suga Y, Honda H, Nagatsuka Y, Ohira T, Tsuboi M, Hirano T (June 2006). "Photodynamic therapy (PDT) for lung cancers". Journal of Thoracic Oncology. 1 (5): 489–93. doi:10.1016/S1556-0864(15)31616-6. PMID 17409904. S2CID 19722977.
  2. Usuda J, Kato H, Okunaka T, Furukawa K, Honda H, Suga Y, Hirata T, Ohira T, Tsuboi M, Hirano T (June 2006). "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer". Journal of Clinical Oncology. 24 (18 suppl): 7229. doi:10.1200/jco.2006.24.18_suppl.7229.
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
SPs/MIs
(M phase)
Block microtubule assembly
Block microtubule disassembly
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
Purine
Pyrimidine
Deoxyribonucleotide
Topoisomerase inhibitors
(S phase)
I
II
II+Intercalation
Crosslinking of DNA
(CCNS)
Alkylating
Platinum-based
Nonclassical
Intercalation
Photosensitizers/PDT
Other
Enzyme inhibitors
Receptor antagonists
Other/ungrouped

Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells

Categories:
Talaporfin Add topic